Janux Therapeutics (NASDAQ:JANX – Get Free Report) and Lucy Scientific Discovery (NASDAQ:LSDI – Get Free Report) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, earnings, analyst recommendations, dividends and profitability.
Volatility and Risk
Janux Therapeutics has a beta of 3.87, indicating that its share price is 287% more volatile than the S&P 500. Comparatively, Lucy Scientific Discovery has a beta of 1.25, indicating that its share price is 25% more volatile than the S&P 500.
Analyst Ratings
This is a breakdown of recent ratings and target prices for Janux Therapeutics and Lucy Scientific Discovery, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Janux Therapeutics | 0 | 0 | 7 | 0 | 3.00 |
| Lucy Scientific Discovery | 0 | 0 | 1 | 0 | 3.00 |
Valuation & Earnings
This table compares Janux Therapeutics and Lucy Scientific Discovery’s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Janux Therapeutics | $8.08 million | 333.30 | -$58.29 million | ($1.34) | -38.76 |
| Lucy Scientific Discovery | $16,732.00 | 89.24 | -$8.99 million | ($7.00) | -0.12 |
Lucy Scientific Discovery has lower revenue, but higher earnings than Janux Therapeutics. Janux Therapeutics is trading at a lower price-to-earnings ratio than Lucy Scientific Discovery, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Janux Therapeutics and Lucy Scientific Discovery’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Janux Therapeutics | -721.18% | -17.88% | -15.95% |
| Lucy Scientific Discovery | N/A | -294.74% | -137.65% |
Insider & Institutional Ownership
75.4% of Janux Therapeutics shares are held by institutional investors. Comparatively, 72.6% of Lucy Scientific Discovery shares are held by institutional investors. 35.4% of Janux Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Summary
Janux Therapeutics beats Lucy Scientific Discovery on 10 of the 13 factors compared between the two stocks.
About Janux Therapeutics
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.
About Lucy Scientific Discovery
Lucy Scientific Discovery Inc., an early stage psychotropics contract manufacturing company, engaged in the research, manufacturing, and commercialization of psychedelic products. The company offers biological raw materials, active pharmaceutical ingredients (APIs), and finished biopharmaceutical products. It also develops and produces highly controlled agricultural grow environments for plant manufacturing and replication applications. The company was formerly known as Hollyweed North Cannabis Inc. and changed its name to Lucy Scientific Discovery Inc. in May 2021. Lucy Scientific Discovery Inc. was incorporated in 2017 and is headquartered in Victoria, Canada.
Receive News & Ratings for Janux Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Janux Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
